Abstract:Merck & Co., Inc. evaluates outcomes of the use of rizatriptan during pregnancy through a Pregnancy Registry in the United States (US) and spontaneous reports for pregnancies reported from sources outside the US. Review of the outcomes of 25 prospective pregnancy reports in the Pregnancy Registry and reports from other sources does not suggest that treatment with rizatriptan predisposes patients to spontaneous abortions or congenital anomalies. However, the number of reports is small. Healthcare providers in t… Show more
“…Although in preclinical studies rizatriptan did not induce developmental effects, it has not been formally tested in pregnant women. International post-marketing surveillance data regarding rizatriptan exposure in pregnant women were recently summarized by Fiore et al for the time period between approval of rizatriptan (1998) and 30 June 2004 [55] . The summary was based on reports of pregnancy temporally associated with rizatriptan exposure as received by the sponsor from clinicians and does not suggest that rizatriptan increased the risk of congenital birth defects.…”
“…The summary was based on reports of pregnancy temporally associated with rizatriptan exposure as received by the sponsor from clinicians and does not suggest that rizatriptan increased the risk of congenital birth defects. Nevertheless, the sample size was insufficient to allow meaningful conclusions and, therefore, the current label precautions for rizatriptan remain unchanged (pregnancy category C, for use in pregnant women only when potential maternal benefit justifies potential fetal risk) [55] .…”
“…Although in preclinical studies rizatriptan did not induce developmental effects, it has not been formally tested in pregnant women. International post-marketing surveillance data regarding rizatriptan exposure in pregnant women were recently summarized by Fiore et al for the time period between approval of rizatriptan (1998) and 30 June 2004 [55] . The summary was based on reports of pregnancy temporally associated with rizatriptan exposure as received by the sponsor from clinicians and does not suggest that rizatriptan increased the risk of congenital birth defects.…”
“…The summary was based on reports of pregnancy temporally associated with rizatriptan exposure as received by the sponsor from clinicians and does not suggest that rizatriptan increased the risk of congenital birth defects. Nevertheless, the sample size was insufficient to allow meaningful conclusions and, therefore, the current label precautions for rizatriptan remain unchanged (pregnancy category C, for use in pregnant women only when potential maternal benefit justifies potential fetal risk) [55] .…”
“…There are almost 100 prospective and retrospective case reports on rizatriptan collected by the Swedish medical birth registry and the producer, and these do not indicate teratogenicity (Fiore 2005).…”
“…Dies galt auch, wenn Triptane während der üb-rigen Schwangerschaft verwendet wurden. Diese Ergebnisse stimmen mit den Ergebnissen anderer prospektiver Datenbanken überein [32][33][34][35] …”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.